1. A second-year resident asks why terbinafine is classified as fungicidal against dermatophytes rather than merely fungistatic. Which of the following best describes the primary mechanism by which terbinafine kills dermatophyte cells?
A) It binds ergosterol directly in the fungal cell membrane, creating pores that cause osmotic lysis
B) It inhibits squalene epoxidase, causing accumulation of squalene and depletion of ergosterol, which is directly toxic to the fungal cell
C) It blocks beta-1,3-glucan synthase, disrupting cell wall integrity and triggering autolytic enzymes
D) It inhibits lanosterol 14-alpha-demethylase, preventing the final steps of ergosterol synthesis
E) It binds tubulin and prevents microtubule polymerization, arresting fungal mitosis
ANSWER: B
Rationale:
Terbinafine inhibits squalene epoxidase (also called squalene monooxygenase), the enzyme that converts squalene to 2,3-oxidosqualene in the ergosterol biosynthesis pathway. Inhibition at this step produces two consequences: squalene accumulates intracellularly to toxic concentrations, and ergosterol synthesis is depleted. The intracellular accumulation of squalene itself is directly toxic and membrane-destabilizing, which is the primary mechanism responsible for the fungicidal activity of terbinafine against dermatophytes, distinguishing it from the azoles that act downstream at lanosterol demethylase and are generally fungistatic.
Option A: Option A is incorrect because direct ergosterol binding describes the mechanism of amphotericin B, not terbinafine; terbinafine acts on an enzyme upstream of ergosterol in the biosynthetic pathway.
Option C: Option C is incorrect because beta-1,3-glucan synthase inhibition is the mechanism of the echinocandins (caspofungin, micafungin, anidulafungin), not terbinafine.
Option D: Option D is incorrect because lanosterol 14-alpha-demethylase inhibition describes the mechanism of the azole antifungals; terbinafine acts at squalene epoxidase, an earlier and distinct step in the same pathway.
Option E: Option E is incorrect because tubulin binding and microtubule disruption describes the mechanism of griseofulvin, not terbinafine.
2. Flucytosine is selectively toxic to fungi despite being converted intracellularly to 5-fluorouracil, a metabolite that is also toxic to mammalian cells. Which mechanism best explains why systemic mammalian toxicity is limited at standard therapeutic doses?
A) Flucytosine is rapidly inactivated by hepatic first-pass metabolism before reaching systemic circulation
B) Mammalian cells express a highly active efflux transporter that expels flucytosine before intracellular conversion can occur
C) The active metabolite 5-fluorouracil is conjugated to glucuronide in mammalian cells, rendering it pharmacologically inert
D) Mammalian cells lack cytosine deaminase, the enzyme that converts flucytosine to 5-fluorouracil, so intracellular conversion does not occur in host tissue
E) Flucytosine is too hydrophilic to cross mammalian cell membranes by passive diffusion and is excluded from host cells
ANSWER: D
Rationale:
Flucytosine enters fungal cells via cytosine permease, an active transport enzyme present on the fungal cell membrane, and is then converted intracellularly to 5-fluorouracil (5-FU) by cytosine deaminase, an enzyme that is present in fungi and some bacteria but essentially absent in mammalian cells. Because mammalian cells lack cytosine deaminase, flucytosine that enters host tissue is not converted to the toxic 5-FU metabolite, which accounts for the selective antifungal toxicity at standard doses. The principal source of systemic 5-FU in patients taking flucytosine is intestinal bacterial conversion in the gut, not host cell metabolism, which is why high flucytosine concentrations (above the toxic threshold) can still produce myelosuppression through gut-derived 5-FU exposure.
Option A: Option A is incorrect because flucytosine has oral bioavailability exceeding 90% and is not subject to significant hepatic first-pass metabolism; it is eliminated almost entirely by renal excretion of unchanged drug.
Option B: Option B is incorrect because selectivity is not conferred by a mammalian efflux transporter; the mechanism is the absence of the converting enzyme cytosine deaminase in host cells.
Option C: Option C is incorrect because glucuronide conjugation inactivating 5-FU is not the operative selectivity mechanism; the key point is that 5-FU is not generated in mammalian cells from flucytosine in the first place.
Option E: Option E is incorrect because flucytosine does enter mammalian cells to some degree; the selectivity mechanism is enzymatic (absence of cytosine deaminase), not a membrane permeability barrier.
3. A pharmacology student asks why griseofulvin is classified as having a mechanism distinct from all other antifungal drugs currently in clinical use. Which statement best describes griseofulvin's mechanism of action?
A) It binds to fungal tubulin and inhibits microtubule polymerization, disrupting the mitotic spindle and arresting cell division
B) It inhibits squalene epoxidase, blocking ergosterol synthesis and causing intracellular squalene accumulation
C) It inhibits beta-1,3-glucan synthase, disrupting fungal cell wall synthesis and causing osmotic lysis
D) It binds ergosterol in the fungal cell membrane, forming ion-permeable channels that cause potassium leakage and cell death
E) It inhibits lanosterol 14-alpha-demethylase, blocking the conversion of lanosterol to ergosterol and depleting the fungal membrane
ANSWER: A
Rationale:
Griseofulvin binds to tubulin monomers and inhibits their polymerization into microtubules, thereby disrupting the mitotic spindle apparatus that is required for fungal nuclear division. This produces multinucleated, abnormally shaped fungal cells that cannot complete cell division, ultimately leading to cell death. This mechanism is mechanistically unique among antifungal agents in clinical use: no other antifungal targets the mitotic spindle. Griseofulvin is selectively concentrated in fungal cells and in keratinized tissues (skin, hair, nails), which is the basis for its clinical efficacy against dermatophytes.
Option B: Option B is incorrect because squalene epoxidase inhibition describes the mechanism of terbinafine, an allylamine; griseofulvin does not act on the ergosterol biosynthesis pathway.
Option C: Option C is incorrect because beta-1,3-glucan synthase inhibition is the mechanism of the echinocandin class (caspofungin, micafungin, anidulafungin).
Option D: Option D is incorrect because ergosterol binding with ion-channel formation describes the mechanism of amphotericin B, not griseofulvin.
Option E: Option E is incorrect because lanosterol 14-alpha-demethylase inhibition is the mechanism of the azole antifungals; griseofulvin does not inhibit any step in the ergosterol biosynthesis pathway.
4. A 52-year-old man presents with confirmed dermatophyte onychomycosis of both great toenails, with nail culture positive for Trichophyton rubrum. He has no significant comorbidities. Which of the following best explains why oral terbinafine is preferred over oral griseofulvin for this indication?
A) Terbinafine is active against Candida species, which may co-infect the nail, whereas griseofulvin has no Candida activity
B) Terbinafine does not require CYP enzyme induction to achieve therapeutic nail concentrations, whereas griseofulvin requires concurrent CYP induction for adequate bioavailability
C) Terbinafine achieves superior mycological cure rates (approximately 70 to 80%) with a 12-week treatment course, compared to griseofulvin's lower cure rates and treatment courses up to 18 months for toenails
D) Terbinafine is the only agent that achieves therapeutic concentrations in the nail bed, whereas griseofulvin distributes only to the nail plate surface
E) Terbinafine is preferred because it is safe in pregnancy, whereas griseofulvin is contraindicated, making terbinafine the universally appropriate choice regardless of patient
ANSWER: C
Rationale:
For dermatophyte onychomycosis, oral terbinafine is preferred over oral griseofulvin based on substantially superior mycological cure rates (approximately 70 to 80% for terbinafine vs. approximately 30 to 40% for griseofulvin) and a markedly shorter treatment duration (12 weeks for toenails with terbinafine vs. up to 18 months for toenails with griseofulvin). Both the efficacy advantage and the convenience of shorter treatment duration make terbinafine the standard of care for this indication.
Option A: Option A is incorrect because terbinafine has limited activity against Candida species; its spectrum is primarily dermatophytes, and Candida nail infections would require a different agent such as an azole. The statement inverts the clinical relevance: it is important to confirm dermatophyte etiology before prescribing terbinafine precisely because it is poorly active against Candida.
Option B: Option B is incorrect because griseofulvin does not require CYP induction for bioavailability; it is a CYP3A4 inducer itself and its bioavailability is affected by dietary fat, not by CYP induction. This option confuses the drug's role as an inducer with a requirement for induction.
Option D: Option D is incorrect because both terbinafine and griseofulvin are deposited in keratinized tissues including the nail bed and nail plate; the preference for terbinafine is based on efficacy and duration, not on a unique distribution advantage.
Option E: Option E is incorrect because terbinafine is not established as safe in pregnancy; it has limited human safety data and is generally avoided in the first trimester, making pregnancy status a factor that complicates use of either agent.
5. An infectious disease consultant is asked whether flucytosine could be used as a single agent to treat cryptococcal meningitis in a patient who cannot tolerate amphotericin B or fluconazole. Which of the following best explains why flucytosine monotherapy is not an acceptable option for serious fungal infections?
A) Flucytosine does not penetrate the blood-brain barrier and cannot achieve therapeutic concentrations in the cerebrospinal fluid
B) Flucytosine is exclusively available as an intravenous formulation and cannot be administered to patients with limited venous access
C) Flucytosine requires co-administration with a polyene antifungal to undergo active transport into fungal cells
D) Flucytosine is metabolized to a toxic intermediate in the liver that accumulates to dangerous levels when the drug is given at doses required for monotherapy efficacy
E) Secondary resistance to flucytosine emerges rapidly when it is used as monotherapy, sometimes within days of initiating therapy against an initially susceptible isolate
ANSWER: E
Rationale:
Flucytosine is never used as monotherapy for serious fungal infections because secondary (acquired) resistance develops rapidly when the drug is used alone against susceptible organisms. Resistance can emerge within days of initiating single-agent therapy as pre-existing resistant mutants within the fungal population are selected under drug pressure. Resistance arises through loss-of-function mutations affecting the flucytosine activation pathway — cytosine permease, cytosine deaminase, or downstream phosphorylation enzymes — any of which prevents the drug from reaching its active intracellular form. Combination with amphotericin B reduces resistance emergence by achieving faster reduction in fungal burden, thereby limiting the probability of selecting resistant mutants.
Option A: Option A is incorrect because flucytosine has excellent central nervous system penetration, achieving cerebrospinal fluid concentrations that are 70 to 85% of concurrent plasma concentrations; this CSF penetration is precisely why it is used as part of the combination induction regimen for cryptococcal meningitis.
Option B: Option B is incorrect because flucytosine is well absorbed orally with bioavailability exceeding 90%, making the oral and intravenous routes pharmacokinetically interchangeable; oral administration is routinely used.
Option C: Option C is incorrect because flucytosine enters fungal cells via its own transporter, cytosine permease, and does not require co-administration of a polyene for cellular uptake; the synergy with amphotericin B occurs because membrane disruption by amphotericin B enhances flucytosine uptake, but this enhancement is additive rather than obligatory for cellular entry.
Option D: Option D is incorrect because flucytosine is not hepatically metabolized to a toxic intermediate; it is eliminated almost entirely as unchanged drug by renal excretion, and its principal toxicity (myelosuppression) arises from gut bacterial conversion to 5-fluorouracil (5-FU), not hepatic metabolism.
6. A 61-year-old woman with major depressive disorder, well controlled on nortriptyline (a tricyclic antidepressant metabolized primarily by CYP2D6), is prescribed a 12-week course of oral terbinafine for toenail onychomycosis. Two weeks into terbinafine therapy she develops dry mouth, urinary hesitancy, and a resting heart rate of 108 beats per minute. Which statement best explains the pharmacokinetic basis for these new symptoms?
A) Terbinafine induces CYP3A4, reducing nortriptyline plasma concentrations and causing a discontinuation syndrome with autonomic features
B) Terbinafine is a potent, mechanism-based (irreversible) inhibitor of CYP2D6, reducing nortriptyline clearance and causing toxic accumulation of the tricyclic antidepressant
C) Terbinafine competes with nortriptyline for plasma protein binding sites, displacing it and transiently increasing free nortriptyline concentrations
D) Terbinafine inhibits P-glycoprotein at the blood-brain barrier, increasing central nervous system penetration of nortriptyline to toxic levels
E) Terbinafine induces CYP1A2, converting nortriptyline to a cardiotoxic hydroxylated metabolite at an accelerated rate
ANSWER: B
Rationale:
Terbinafine is a potent inhibitor of CYP2D6 (cytochrome P450 2D6) and the inhibition is mechanism-based, meaning it is irreversible — terbinafine covalently inactivates the enzyme, and its inhibitory effect persists for weeks after terbinafine is discontinued while new CYP2D6 enzyme is synthesized. Nortriptyline is a CYP2D6 substrate with a narrow therapeutic index; when CYP2D6 activity is substantially reduced, nortriptyline clearance falls and plasma concentrations rise. The symptoms described — dry mouth, urinary hesitancy, and tachycardia — are classic anticholinergic toxicity features of elevated tricyclic antidepressant concentrations. This interaction is clinically important and requires either dose reduction of nortriptyline, enhanced monitoring, or use of an alternative antifungal agent.
Option A: Option A is incorrect because terbinafine does not induce CYP3A4; its primary CYP interaction is potent inhibition of CYP2D6. Nortriptyline is not a CYP3A4 substrate to a clinically relevant degree, and CYP induction would reduce rather than increase drug concentrations, producing withdrawal features rather than toxicity.
Option C: Option C is incorrect because protein binding displacement is rarely a clinically significant mechanism for drug interactions at therapeutic concentrations; the dominant interaction here is CYP2D6-mediated metabolic inhibition causing accumulation.
Option D: Option D is incorrect because P-glycoprotein inhibition by terbinafine is not a clinically established mechanism, and CNS penetration changes would not produce the peripheral anticholinergic features (urinary hesitancy, tachycardia) that are evident.
Option E: Option E is incorrect because terbinafine inhibits CYP2D6, not CYP1A2, and does not generate toxic nortriptyline metabolites through CYP1A2 induction; the mechanism is reduced clearance through CYP2D6 inhibition, not enhanced conversion to a toxic product.
7. A pediatric patient is prescribed microsize griseofulvin for tinea capitis. The pharmacist asks the prescribing physician about specific administration instructions that affect drug absorption. Which of the following best describes the pharmacokinetic basis for the required instructions?
A) Griseofulvin must be taken on an empty stomach because food activates first-pass hepatic metabolism that reduces bioavailability below therapeutic levels
B) Griseofulvin must be taken with acidic beverages such as orange juice because gastric acid catalyzes dissolution of the microsize particles before intestinal absorption
C) Griseofulvin must be taken at least two hours before or after dairy products because calcium ions chelate griseofulvin and prevent intestinal absorption
D) Griseofulvin microsize formulation must be taken with a fatty meal because fat stimulates bile secretion and increases intestinal solubilization of this lipophilic drug, substantially improving bioavailability
E) Griseofulvin must be taken with a large volume of water to prevent precipitation in the small intestine, which is the rate-limiting step for absorption
ANSWER: D
Rationale:
Griseofulvin is a lipophilic drug with variable oral bioavailability that is significantly enhanced when administered with a high-fat meal. Dietary fat stimulates bile acid secretion and increases intestinal lipid content, both of which improve the solubilization of lipophilic drug particles in the intestinal lumen — a prerequisite for absorption. For microsize griseofulvin, bioavailability ranges from approximately 25 to 70% depending on fat content of co-administered food; patients are routinely instructed to take it with a fatty meal such as whole milk, ice cream, or a meal with substantial fat content. The ultramicrosize formulation (Gris-PEG) has more consistent and complete absorption (approximately 70%) and is less dependent on fat co-administration, but even for this formulation fat-containing meals are generally recommended. Failure to take microsize griseofulvin with fatty food can result in subtherapeutic plasma concentrations and treatment failure.
Option A: Option A is incorrect because griseofulvin absorption is enhanced, not impaired, by food; taking it on an empty stomach reduces bioavailability.
Option B: Option B is incorrect because acidic beverages do not play a role in griseofulvin absorption; the limiting factor is lipid solubilization, not pH-dependent dissolution.
Option C: Option C is incorrect because calcium chelation is a pharmacokinetic interaction associated with tetracycline and fluoroquinolone antibiotics, not griseofulvin; griseofulvin does not form chelates with divalent cations.
Option E: Option E is incorrect because precipitation in the small intestine is not the rate-limiting step for griseofulvin absorption; lipid solubilization facilitated by bile acids and dietary fat is the key determinant of microsize absorption.
8. A patient with cryptococcal meningitis is receiving amphotericin B plus flucytosine for induction therapy. Therapeutic drug monitoring (TDM) of flucytosine is ordered. Which of the following correctly states the target peak concentration range and the toxic threshold that TDM is designed to avoid?
A) Target 2-hour post-dose peak: 25 to 50 mg/L; toxic threshold: trough concentrations above 100 mg/L, at which myelosuppression risk increases sharply
B) Target trough concentration: 10 to 20 mg/L; toxic threshold: peak concentrations above 40 mg/L, which cause irreversible nephrotoxicity
C) Target steady-state average concentration: 5 to 15 mg/L; toxic threshold: any concentration above 30 mg/L, which triggers hepatic failure
D) Target pre-dose trough: 2 to 8 mg/L; toxic threshold: peak concentrations above 50 mg/L, associated with neurotoxicity and seizures
E) Target 1-hour post-dose peak: 80 to 120 mg/L; toxic threshold: trough concentrations below 25 mg/L, which permit resistance emergence
ANSWER: A
Rationale:
For flucytosine TDM, the target 2-hour post-dose (peak) concentration is 25 to 50 mg/L (some protocols targeting CSF infections use 40 to 60 mg/L). The critical toxic threshold is trough concentrations exceeding 100 mg/L, above which the risk of myelosuppression — leukopenia, thrombocytopenia, and anemia — increases sharply. Myelosuppression arises because intestinal bacteria convert flucytosine to 5-fluorouracil (5-FU) in the gut, and at high systemic drug concentrations, sufficient 5-FU is generated to suppress bone marrow. The risk is concentration-dependent, which makes TDM an effective tool for maintaining efficacy while avoiding toxicity. TDM is mandatory in patients with impaired or fluctuating renal function (since flucytosine is renally cleared), in those receiving concurrent nephrotoxins such as amphotericin B, and in neonates.
Option B: Option B is incorrect because flucytosine TDM targets peak concentrations (2-hour post-dose), not trough concentrations, and nephrotoxicity at peak concentrations above 40 mg/L is not the relevant toxicity concern; nephrotoxicity is associated with amphotericin B in this combination, not with flucytosine directly.
Option C: Option C is incorrect because flucytosine monitoring uses peak concentrations at a defined post-dose interval, not steady-state averages, and hepatic failure at concentrations above 30 mg/L misrepresents both the target and the threshold; hepatotoxicity is a recognized but secondary toxicity, not the primary TDM-driving concern.
Option D: Option D is incorrect because flucytosine TDM is based on peak (post-dose) rather than pre-dose trough values, and neurotoxicity and seizures are not the primary flucytosine toxicities — myelosuppression is.
Option E: Option E is incorrect because target peaks of 80 to 120 mg/L would place patients well into the toxic range; the correct target peak is 25 to 50 mg/L, not 80 to 120 mg/L.
9. A 70-year-old man with stage 3 chronic kidney disease (CrCl (creatinine clearance) 38 mL/min) is diagnosed with dermatophyte onychomycosis. The treating physician considers prescribing oral terbinafine. Which statement best describes the appropriate prescribing approach in this patient?
A) Terbinafine is absolutely contraindicated in CrCl below 50 mL/min and should not be prescribed; an azole antifungal should be substituted
B) No dose adjustment is required because terbinafine is metabolized entirely by CYP2D6 and renal function does not affect its clearance
C) The standard 250 mg once-daily dose should be reduced by approximately 50% because terbinafine clearance is reduced in moderate renal impairment, increasing drug exposure
D) Terbinafine should be administered at full dose but the treatment course extended to 24 weeks to compensate for reduced tissue penetration in patients with renal impairment
E) Terbinafine is the preferred agent and requires no modification; renal dosing adjustments apply only to flucytosine, not to allylamine antifungals
ANSWER: C
Rationale:
Terbinafine requires dose reduction in patients with moderate-to-severe renal impairment. Current prescribing guidance recommends reducing the dose by approximately 50% (to 125 mg once daily) when CrCl falls below 50 mL/min, and the drug should generally be avoided in severe renal impairment. Although terbinafine is extensively metabolized by the liver and its metabolites are eliminated renally, impaired renal clearance leads to accumulation of both parent drug and metabolites, increasing systemic exposure and the risk of adverse effects including hepatotoxicity. This patient with CrCl of 38 mL/min falls in the range requiring dose reduction.
Option A: Option A is incorrect because terbinafine is not absolutely contraindicated below CrCl 50 mL/min; dose reduction rather than substitution is the recommended approach, and azole substitution is not automatically indicated.
Option B: Option B is incorrect because although terbinafine undergoes hepatic metabolism, renal function does affect drug exposure through reduced elimination of metabolites; a claim that renal function is entirely irrelevant is inaccurate and clinically dangerous for patients with moderate-to-severe impairment.
Option D: Option D is incorrect because extending the treatment course does not address the pharmacokinetic problem of increased drug and metabolite exposure due to reduced renal clearance; dose reduction is the appropriate modification, not course extension.
Option E: Option E is incorrect because the claim that renal dosing adjustments apply only to flucytosine is false; terbinafine does require dose adjustment in renal impairment, and prescribing at full dose without modification in a patient with CrCl 38 mL/min is inappropriate.
10. A 24-year-old woman using a combined oral contraceptive (OC) for birth control is prescribed a 10-week course of griseofulvin for tinea capitis caused by Microsporum canis. She asks whether her contraceptive will still be effective during treatment. Which pharmacokinetic mechanism explains why additional contraceptive precautions are required?
A) Griseofulvin inhibits CYP2D6, reducing the conversion of progestins to their active forms and rendering the OC pharmacodynamically inactive
B) Griseofulvin binds estrogen receptors in the gut wall, preventing first-pass uptake of ethinylestradiol and reducing its systemic bioavailability
C) Griseofulvin activates P-glycoprotein efflux pumps in the intestinal mucosa, pumping oral contraceptive components back into the intestinal lumen before systemic absorption occurs
D) Griseofulvin inhibits hepatic CYP3A4, paradoxically increasing OC plasma concentrations above the therapeutic window and reducing the LH surge required for contraceptive efficacy
E) Griseofulvin induces CYP3A4 and CYP1A2 (cytochrome P450 1A2), increasing the hepatic metabolism of ethinylestradiol and reducing its plasma concentrations to levels insufficient for reliable contraception
ANSWER: E
Rationale:
Griseofulvin is an inducer of CYP3A4 (cytochrome P450 3A4) and CYP1A2. Ethinylestradiol, the estrogen component of combined oral contraceptives, is metabolized substantially by CYP3A4. When griseofulvin induces CYP3A4 and CYP1A2, the rate of ethinylestradiol metabolism increases, reducing its plasma concentrations to levels that may be insufficient to reliably suppress ovulation and maintain contraceptive efficacy. Patients of childbearing potential must be counseled to use a barrier method (such as condoms) during griseofulvin therapy and for at least one month after completing treatment, because CYP induction persists beyond the last dose as induced enzyme activity returns gradually to baseline. This interaction has been associated with cases of unintended pregnancy.
Option A: Option A is incorrect because griseofulvin does not inhibit CYP2D6 and progestins are not activated by CYP2D6; the relevant interaction involves CYP3A4 induction and ethinylestradiol metabolism.
Option B: Option B is incorrect because griseofulvin does not bind estrogen receptors; it is an antifungal that acts on fungal tubulin, not on host steroid receptor pathways.
Option C: Option C is incorrect because griseofulvin-mediated P-glycoprotein activation is not an established mechanism for this interaction; the primary mechanism is hepatic CYP enzyme induction reducing systemic ethinylestradiol concentrations.
Option D: Option D is incorrect because griseofulvin induces (not inhibits) CYP3A4, and CYP3A4 induction reduces rather than increases OC concentrations; furthermore, the concern is inadequate contraception from reduced hormone levels, not excess hormone from inhibition.
11. A patient with HIV-associated cryptococcal meningitis is receiving amphotericin B plus flucytosine induction therapy. On day 10 of treatment, a complete blood count (CBC) shows a white blood cell count of 1.8 × 10⁹/L (normal 4.5–11 × 10⁹/L) and platelets of 62 × 10⁹/L (normal 150–400 × 10⁹/L). A flucytosine level drawn two hours after the previous dose is 118 mg/L. Which statement best explains the mechanism of this complication?
A) Amphotericin B directly suppresses bone marrow stem cell proliferation through ergosterol binding to mitochondrial membranes in hematopoietic precursors
B) Flucytosine plasma concentrations above the toxic threshold lead to gut bacterial conversion of flucytosine to 5-fluorouracil (5-FU), which systemically suppresses bone marrow at elevated drug concentrations
C) The combination of amphotericin B and flucytosine competitively inhibits dihydrofolate reductase in hematopoietic precursors, depleting folate cofactors required for DNA synthesis
D) HIV-associated immune reconstitution inflammatory syndrome (IRIS) triggered by cryptococcal antigen clearance causes bone marrow suppression through cytokine-mediated inhibition of hematopoiesis
E) Flucytosine is converted by hepatic CYP3A4 to a myelotoxic metabolite that accumulates when renal clearance of the parent compound is impaired
ANSWER: B
Rationale:
The principal dose-limiting toxicity of flucytosine is myelosuppression — leukopenia, thrombocytopenia, and anemia — and it is concentration-dependent. Intestinal bacteria convert flucytosine to 5-fluorouracil (5-FU) in the gastrointestinal tract; at elevated systemic flucytosine concentrations, sufficient 5-FU is generated and absorbed to suppress bone marrow, which contains rapidly dividing hematopoietic progenitor cells that are sensitive to 5-FU's thymidylate synthase inhibition and RNA disruption. In this patient, the 2-hour post-dose flucytosine level of 118 mg/L exceeds the toxic threshold of 100 mg/L, directly explaining the myelosuppression. The concurrent use of amphotericin B, which is nephrotoxic, further reduces renal clearance of flucytosine, increasing its plasma concentrations. TDM (therapeutic drug monitoring) is mandatory precisely to detect this scenario before severe cytopenias develop.
Option A: Option A is incorrect because amphotericin B does not suppress bone marrow through ergosterol binding to hematopoietic cell mitochondria; amphotericin B targets fungal ergosterol and its primary toxicities are nephrotoxicity and infusion-related reactions, not direct myelosuppression.
Option C: Option C is incorrect because neither amphotericin B nor flucytosine inhibits dihydrofolate reductase; that mechanism describes trimethoprim and methotrexate.
Option D: Option D is incorrect because while IRIS is a recognized complication in HIV patients being treated for cryptococcal meningitis, it typically produces inflammatory manifestations (fever, worsening meningitis, lymphadenopathy) rather than isolated cytopenias, and the elevated flucytosine level in this scenario provides a direct pharmacological explanation.
Option E: Option E is incorrect because flucytosine is not metabolized by CYP3A4 to a myelotoxic metabolite; it is eliminated almost entirely by renal excretion of unchanged drug, and the myelotoxic intermediate (5-FU) arises from gut bacterial conversion, not hepatic metabolism.
12. An HIV-positive patient with CD4 count of 28 cells/µL presents with headache, fever, and confusion. Lumbar puncture confirms cryptococcal meningitis. Amphotericin B is available. Which of the following represents the WHO (World Health Organization) 2022 preferred induction regimen for this patient?
A) Fluconazole 800 mg orally once daily for four weeks as monotherapy induction, followed by consolidation with lower-dose fluconazole
B) Voriconazole 6 mg/kg IV every 12 hours for two loading doses then 4 mg/kg every 12 hours, combined with micafungin for synergistic coverage
C) Amphotericin B monotherapy at 0.7 to 1 mg/kg IV daily for two weeks, which achieves CSF sterilization through membrane-disrupting fungicidal activity without requiring a second agent
D) Amphotericin B (preferably liposomal) combined with flucytosine 25 mg/kg orally four times daily for one to two weeks, which achieves superior early fungicidal activity and improved survival compared to monotherapy or fluconazole-based regimens
E) Micafungin 100 mg IV once daily combined with fluconazole 400 mg orally once daily for two weeks, providing dual-mechanism coverage targeting both cell wall and membrane ergosterol synthesis
ANSWER: D
Rationale:
The WHO 2022 guidelines for cryptococcal disease recommend amphotericin B (preferably liposomal formulation, which is less nephrotoxic than conventional deoxycholate) combined with flucytosine 25 mg/kg orally four times daily as the preferred induction regimen for cryptococcal meningitis where both drugs are available. This recommendation is supported by randomized clinical trial evidence — including the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial — demonstrating that the combination achieves superior early fungicidal activity (faster CSF sterilization) and improved 10-week survival compared to amphotericin B monotherapy or fluconazole-based regimens. The mechanistic basis for synergy is that amphotericin B disrupts the fungal cell membrane, enhancing flucytosine uptake and potentiating its antimetabolite effect at the level of nucleic acid synthesis.
Option A: Option A is incorrect because fluconazole monotherapy, even at high doses, is inferior to amphotericin B-based combination therapy for induction; monotherapy fluconazole is the option only when neither amphotericin B nor flucytosine can be used, and even then outcomes are substantially worse.
Option B: Option B is incorrect because voriconazole combined with micafungin is not a guideline-endorsed regimen for cryptococcal meningitis induction; voriconazole has activity against Cryptococcus but is not part of standard combination induction protocols, and echinocandins have limited activity against Cryptococcus.
Option C: Option C is incorrect because amphotericin B monotherapy, though active, is inferior to the combination with flucytosine in terms of early fungicidal activity and survival; the WHO 2022 guidelines explicitly recommend the combination over monotherapy where flucytosine is available.
Option E: Option E is incorrect because micafungin combined with fluconazole is not a guideline-endorsed induction regimen; echinocandins have minimal activity against Cryptococcus neoformans and are not appropriate as components of cryptococcal meningitis induction therapy.
13. A 48-year-old man on week 8 of terbinafine therapy for onychomycosis develops fatigue, right upper quadrant discomfort, and mild jaundice. Liver function tests show ALT (alanine aminotransferase) 4.2 times the upper limit of normal (ULN) and total bilirubin elevated. Which of the following best describes the appropriate management and the mechanism of this complication?
A) Terbinafine should be discontinued immediately; the hepatotoxicity is idiosyncratic and immune-mediated rather than dose-dependent, and the drug cannot be safely continued in the presence of symptomatic liver injury with ALT above 3 times ULN
B) Terbinafine dose should be reduced by 50% and liver function tests repeated in two weeks; the hepatotoxicity is dose-dependent and will resolve with dose reduction without requiring cessation
C) Terbinafine can be continued at full dose with the addition of N-acetylcysteine (NAC) to replenish hepatic glutathione stores depleted by the drug's reactive metabolites
D) Terbinafine hepatotoxicity at this level is a class effect shared by all antifungals and requires substitution with an echinocandin, which is the only antifungal class without hepatotoxic potential
E) No change to terbinafine therapy is required; transient ALT elevations below 5 times ULN are expected during the first 12 weeks of treatment and are part of the therapeutic response
ANSWER: A
Rationale:
Terbinafine carries a rare but serious risk of hepatotoxicity, including symptomatic hepatitis, cholestatic jaundice, and hepatic failure. Current prescribing guidance specifies that terbinafine should be discontinued if ALT or AST (aspartate aminotransferase) rises above 3 times ULN with symptoms, or above 5 times ULN even without symptoms. This patient has ALT at 4.2 times ULN with symptoms (fatigue, right upper quadrant discomfort, jaundice), which meets the threshold for immediate discontinuation. The hepatotoxicity is idiosyncratic and immune-mediated in mechanism, meaning it is unpredictable, not dose-dependent, and cannot be managed by dose reduction alone. The incidence of serious liver injury is estimated at approximately 1 in 50,000 to 1 in 120,000 treated patients, making it uncommon but important given the large population treated for onychomycosis.
Option B: Option B is incorrect because terbinafine hepatotoxicity is idiosyncratic and immune-mediated, not dose-dependent; dose reduction does not safely manage ongoing immune-mediated liver injury, and symptomatic hepatitis above the ALT threshold requires drug discontinuation rather than continuation at any dose.
Option C: Option C is incorrect because NAC is used for acetaminophen hepatotoxicity through a well-defined glutathione-depletion mechanism, not for terbinafine-induced immune-mediated hepatic injury, which has a different pathophysiology; continuing terbinafine with NAC co-administration is not an established management strategy.
Option D: Option D is incorrect because terbinafine hepatotoxicity is not a class effect of all antifungals; the echinocandins have a different hepatotoxicity profile and are not indicated for dermatophyte onychomycosis.
Option E: Option E is incorrect because ALT elevations with symptoms at 4.2 times ULN are not expected or acceptable during routine terbinafine therapy; the prescribing threshold for discontinuation with symptoms is ALT above 3 times ULN, and waiting until 5 times ULN is only acceptable in the absence of symptoms.
14. A pharmacist reviews the medication profile of a patient receiving flucytosine for cryptococcal meningitis who has developed acute kidney injury (AKI). The pharmacist notes that flucytosine requires urgent dose adjustment. Which pharmacokinetic property of flucytosine makes renal dose adjustment mandatory?
A) Flucytosine undergoes extensive hepatic glucuronidation, and renal failure inhibits glucuronide excretion, causing the parent compound to accumulate through enterohepatic recycling
B) Flucytosine is converted to a nephrotoxic metabolite by CYP3A4, and renal impairment reduces clearance of this metabolite, creating a toxicity feedback loop
C) More than 90% of a flucytosine dose is eliminated by renal excretion of unchanged drug; renal impairment therefore directly reduces flucytosine clearance, causing drug accumulation and increasing the risk of concentration-dependent myelosuppression
D) Flucytosine is moderately protein-bound, and renal failure reduces albumin synthesis, increasing the free fraction of drug and necessitating dose reduction to maintain equivalent unbound drug exposure
E) Flucytosine undergoes tubular secretion that competes with creatinine elimination; in renal impairment, creatinine accumulation saturates the tubular transporter and reduces flucytosine excretion indirectly
ANSWER: C
Rationale:
Flucytosine is eliminated almost entirely by renal excretion of unchanged drug; more than 90% of a dose appears in urine as intact flucytosine, with minimal hepatic metabolism. This near-exclusive renal elimination means that any reduction in glomerular filtration rate (GFR) directly reduces flucytosine clearance, causing plasma and tissue concentrations to rise. Because flucytosine toxicity — principally myelosuppression — is concentration-dependent, accumulation above the toxic threshold (trough above 100 mg/L) increases the risk of leukopenia and thrombocytopenia. In AKI, renal function may be fluctuating, making fixed creatinine-based dose adjustment tables unreliable; TDM (therapeutic drug monitoring) is therefore the primary guide to dosing when renal function is changing rapidly.
Option A: Option A is incorrect because flucytosine does not undergo hepatic glucuronidation; it is excreted as unchanged drug and is not subject to significant hepatic conjugation or enterohepatic recycling.
Option B: Option B is incorrect because flucytosine is not metabolized by CYP3A4 to a nephrotoxic intermediate; its primary clearance pathway is renal excretion of unchanged drug, and the myelotoxic intermediate (5-FU) arises from gut bacterial conversion, not hepatic oxidation.
Option D: Option D is incorrect because flucytosine is minimally protein-bound (approximately 4%), so changes in albumin concentration have negligible impact on its free fraction or total drug exposure; reduced protein binding is not the pharmacokinetic basis for renal dose adjustment.
Option E: Option E is incorrect because although flucytosine undergoes some tubular handling, the dominant mechanism requiring dose adjustment is reduced glomerular filtration of unchanged drug, not tubular competition with creatinine.
15. A physician is about to prescribe griseofulvin for tinea capitis in an outpatient. Before prescribing, which two absolute contraindications must be excluded by history?
A) Sulfa allergy and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because griseofulvin contains a sulfonamide ring that causes hemolysis in G6PD-deficient patients
B) Prior treatment with ketoconazole and concurrent use of itraconazole, because cumulative azole exposure triggers cross-reactive griseofulvin hepatotoxicity
C) Penicillin allergy and beta-lactam sensitivity, because griseofulvin is derived from Penicillium griseofulvum and shares cross-reactive epitopes with penicillin antibiotics
D) Active tuberculosis and rifampin co-administration, because rifampin accelerates griseofulvin metabolism to a toxic quinone metabolite causing irreversible hepatic necrosis
E) Pregnancy and hepatocellular failure or porphyria, because griseofulvin is teratogenic in animal studies and is contraindicated in conditions involving hepatic dysfunction or porphyrin synthesis
ANSWER: E
Rationale:
Griseofulvin has two principal absolute contraindications that must be excluded before prescribing: pregnancy and hepatocellular failure or porphyria. Griseofulvin is teratogenic in animal studies, and while definitive human teratogenicity data are limited, the drug is contraindicated throughout pregnancy based on precautionary grounds; patients of childbearing potential must use effective non-hormonal contraception during and for one month after treatment, given that griseofulvin also reduces oral contraceptive efficacy through CYP (cytochrome P450) enzyme induction. Griseofulvin is also contraindicated in patients with hepatocellular failure because it undergoes hepatic CYP3A4-mediated metabolism and carries hepatotoxic potential in the setting of pre-existing severe hepatic impairment. Porphyria is an absolute contraindication because griseofulvin induces porphyrin synthesis, which can precipitate acute porphyric crises in susceptible patients; this is the basis for excluding any history of acute or latent porphyria before prescribing.
Option A: Option A is incorrect because griseofulvin does not contain a sulfonamide ring and does not cause hemolysis in G6PD-deficient patients; sulfonamide cross-reactivity and G6PD-related hemolysis are associated with sulfa drugs, not with griseofulvin.
Option B: Option B is incorrect because prior azole exposure does not create a contraindication to griseofulvin, and griseofulvin hepatotoxicity is not triggered by cumulative azole use.
Option C: Option C is incorrect because although griseofulvin is derived from Penicillium griseofulvum, it does not share cross-reactive beta-lactam epitopes with penicillin and is not contraindicated in patients with penicillin allergy; the molecular structure of griseofulvin bears no pharmacologically relevant similarity to penicillin.
Option D: Option D is incorrect because rifampin co-administration does not generate a toxic quinone metabolite from griseofulvin causing hepatic necrosis; while enzyme-inducing drugs can affect griseofulvin metabolism, this is not an absolute contraindication and the mechanism described is fabricated.
16. A 9-year-old child presents with a scaling, pruritic scalp lesion with broken hair shafts, and fungal culture confirms Trichophyton tonsurans tinea capitis. The parent asks why topical antifungal shampoo alone is being refused and why systemic treatment is required. Which of the following correctly explains both the need for systemic therapy and the preferred systemic agent for this organism?
A) Topical therapy fails because T. tonsurans secretes a biofilm matrix that prevents antifungal penetration; oral griseofulvin is preferred because it disrupts biofilm formation through microtubule inhibition
B) Topical antifungals cannot reach the hair follicle where the dermatophyte resides; oral terbinafine is preferred over griseofulvin for T. tonsurans tinea capitis because terbinafine achieves superior mycological cure rates for this species
C) Topical agents are ineffective because T. tonsurans is intrinsically resistant to all topical azoles and allylamines; oral griseofulvin, which has a unique intracellular mechanism, overcomes this topical resistance
D) Systemic therapy is required because tinea capitis involves the nail matrix in children, which cannot be reached by topical agents; terbinafine and griseofulvin are equally efficacious and the choice is arbitrary
E) Topical therapy is refused only for cosmetic reasons related to application compliance; the pharmacological rationale supports topical therapy alone for mild cases, and either griseofulvin or terbinafine is added only for extensive scalp involvement
ANSWER: B
Rationale:
Tinea capitis requires systemic antifungal therapy because dermatophytes invade the hair follicle and hair shaft, anatomical sites that topical agents cannot penetrate in therapeutic concentrations; topical treatment alone is insufficient regardless of disease severity. For tinea capitis caused by Trichophyton tonsurans, which is the most common cause in many regions including North America, oral terbinafine has demonstrated superior mycological cure rates compared to griseofulvin in comparative trials and is now preferred in many guidelines, particularly for T. tonsurans and T. violaceum. The recommended terbinafine dosing in children is weight-based: below 20 kg use 62.5 mg once daily; 20 to 40 kg use 125 mg once daily; above 40 kg use 250 mg once daily, for a minimum of four weeks. Griseofulvin remains an acceptable alternative and is preferred for Microsporum canis-caused tinea capitis, where terbinafine has lower efficacy.
Option A: Option A is incorrect because dermatophytes do not form clinically relevant biofilms comparable to bacterial biofilms, and griseofulvin's mechanism (tubulin binding) is not related to biofilm disruption; the need for systemic therapy is anatomical (hair follicle invasion), not related to biofilm barriers.
Option C: Option C is incorrect because T. tonsurans is not intrinsically resistant to topical allylamines or azoles; the reason systemic therapy is required is the anatomical inaccessibility of the hair follicle to topical agents, not organism resistance.
Option D: Option D is incorrect because tinea capitis does not involve the nail matrix; the nail is a separate anatomical site. Terbinafine and griseofulvin are not equally efficacious for T. tonsurans — terbinafine is preferred for this species.
Option E: Option E is incorrect because the indication for systemic therapy is pharmacological and anatomical, not cosmetic; topical therapy alone is genuinely inadequate because it cannot penetrate the hair follicle regardless of disease extent.
17. A clinical pharmacologist explains why flucytosine is particularly valuable as a partner agent in the treatment of cryptococcal meningitis compared to many other antifungal drugs. Which pharmacokinetic property of flucytosine is most relevant to this clinical advantage?
A) Flucytosine achieves cerebrospinal fluid (CSF) concentrations that are 70 to 85% of concurrent plasma concentrations, providing effective antifungal drug levels at the site of infection within the central nervous system
B) Flucytosine has a plasma half-life of less than two hours, allowing rapid dose titration based on real-time TDM results without risk of drug accumulation between doses
C) Flucytosine is highly lipophilic with a large volume of distribution exceeding 10 liters per kilogram (L/kg), allowing rapid intracellular penetration into brain parenchymal cells infected with Cryptococcus
D) Flucytosine is an active substrate of P-glycoprotein (P-gp) at the blood-brain barrier, and co-administration with amphotericin B inhibits P-gp, enabling paradoxically enhanced CNS penetration in combination
E) Flucytosine undergoes active transport into the CSF by a specific choroid plexus carrier protein that concentrates the drug in CSF to levels exceeding plasma concentrations, providing a pharmacokinetic advantage over plasma-based dosing targets
ANSWER: A
Rationale:
Flucytosine penetrates the central nervous system (CNS) exceptionally well, achieving CSF concentrations that are 70 to 85% of concurrent plasma concentrations. This high CSF penetration is a direct consequence of its physicochemical properties: flucytosine is minimally protein-bound (approximately 4%), hydrophilic with a volume of distribution approximating total body water (approximately 0.6 L/kg), and small enough to cross the blood-brain barrier effectively. Because therapeutic CSF drug concentrations are essential for efficacy in cryptococcal meningitis — where the organism replicates within the subarachnoid space and ventricles — this penetration characteristic is a major reason flucytosine is an effective partner agent in induction therapy.
Option B: Option B is incorrect because flucytosine has a plasma half-life of approximately 3 to 6 hours in patients with normal renal function, not less than two hours; while TDM is used to guide dosing, rapid half-life is not cited as a clinical advantage in cryptococcal meningitis.
Option C: Option C is incorrect because flucytosine is hydrophilic, not lipophilic, and has a modest volume of distribution approximating total body water; a large volume of distribution (high lipophilicity) actually describes drugs like amphotericin B lipid complex or voriconazole, not flucytosine.
Option D: Option D is incorrect because flucytosine is not an active P-glycoprotein (P-gp) substrate, and amphotericin B does not enhance CNS penetration of flucytosine through P-gp inhibition; the CNS penetration of flucytosine is an intrinsic property of the molecule, not dependent on co-administered agents.
Option E: Option E is incorrect because flucytosine does not rely on an active choroid plexus carrier for CNS penetration, nor does it achieve CSF concentrations that exceed plasma; the correct value is 70 to 85% of plasma concentrations, achieved through passive diffusion consistent with its low protein binding and hydrophilic character.
18. A 35-year-old man is prescribed griseofulvin for tinea capitis. During counseling the physician mentions a specific adverse interaction with alcohol consumption. Which of the following best describes this interaction and its mechanism?
A) Alcohol is a CYP3A4 inducer that accelerates griseofulvin metabolism, reducing plasma concentrations below therapeutic levels and causing treatment failure
B) Concurrent alcohol use saturates hepatic glucuronidation, diverting griseofulvin toward a nephrotoxic sulfate conjugate pathway that causes acute kidney injury
C) Alcohol inhibits the cytosine permease transporter in dermatophytes, reducing intracellular griseofulvin accumulation and causing antifungal resistance
D) Concurrent alcohol use with griseofulvin produces a disulfiram-like reaction in some patients, characterized by flushing, tachycardia, and nausea, mediated by inhibition of aldehyde dehydrogenase (ALDH2)
E) Alcohol increases gastric motility and reduces griseofulvin contact time in the small intestine, decreasing absorption by more than 80% and making concurrent alcohol use an absolute contraindication
ANSWER: D
Rationale:
Griseofulvin is associated with a disulfiram-like reaction when combined with alcohol in some patients. The reaction is characterized by flushing, tachycardia, nausea, and sometimes hypotension — the same symptom complex produced by disulfiram (Antabuse) in patients who consume alcohol — and is mediated by inhibition of aldehyde dehydrogenase (ALDH2), the enzyme responsible for converting acetaldehyde (the primary metabolite of ethanol oxidation) to acetate. When ALDH2 is inhibited, acetaldehyde accumulates in the circulation, producing the characteristic vasomotor symptoms. Patients prescribed griseofulvin should be counseled to avoid alcohol during the entire treatment course.
Option A: Option A is incorrect because chronic heavy alcohol use does induce CYP enzymes, but griseofulvin's primary interaction with alcohol is the acute disulfiram-like reaction, not a pharmacokinetic reduction in griseofulvin plasma concentrations; moreover, griseofulvin is itself a CYP3A4 inducer.
Option B: Option B is incorrect because griseofulvin metabolism does not involve significant glucuronidation being diverted to a nephrotoxic sulfate conjugate pathway; the primary metabolic pathway is CYP3A4-mediated demethylation to 6-demethylgriseofulvin, and nephrotoxicity from a sulfate conjugate is not a recognized adverse effect.
Option C: Option C is incorrect because griseofulvin acts on fungal tubulin, not through cytosine permease; cytosine permease is the transport mechanism for flucytosine, not for griseofulvin.
Option E: Option E is incorrect because although fat with meals improves griseofulvin absorption, alcohol does not reduce absorption by 80% through accelerated gastric motility; the alcohol interaction of clinical concern is the disulfiram-like reaction, not a pharmacokinetic absorption interaction.
19. A 55-year-old woman presents with thickened, discolored toenails. The physician prescribes oral terbinafine empirically without obtaining nail sampling. Four weeks later, nail culture from a pre-treatment sample taken by a colleague returns positive for Candida albicans. Which statement best explains the clinical implication of this finding?
A) The positive Candida culture is an expected finding; terbinafine has broad-spectrum activity against Candida species and the current treatment course should be completed without modification
B) Terbinafine is fungistatic against Candida species and a longer 24-week course should replace the standard 12-week course to achieve adequate mycological cure
C) Terbinafine has poor activity against Candida species; the diagnosis of Candida onychomycosis means the prescribed terbinafine is unlikely to be effective and the treatment regimen should be reconsidered with an azole antifungal
D) This finding invalidates the clinical diagnosis of onychomycosis; Candida in nail culture always represents contamination and no antifungal treatment is required
E) Candida albicans is a dermatophyte species in the Trichophyton genus and is within terbinafine's spectrum; no change in treatment is needed
ANSWER: C
Rationale:
Terbinafine's antifungal spectrum is primarily against dermatophytes (Trichophyton, Microsporum, Epidermophyton species); it has poor activity against Candida species. This is a clinically critical limitation because nail infections can be caused by dermatophytes, non-dermatophyte molds, or Candida, and the appearance of the nail does not reliably distinguish between etiologies. For Candida onychomycosis, oral fluconazole or itraconazole (azole antifungals that inhibit ergosterol synthesis at CYP51/lanosterol demethylase) are appropriate treatment options; terbinafine, which targets squalene epoxidase, is not reliably effective against Candida because the organism's response to squalene epoxidase inhibition differs from dermatophytes. This case illustrates why current prescribing guidance recommends nail sampling for fungal culture or PCR (polymerase chain reaction) testing before initiating terbinafine, precisely to confirm dermatophyte etiology and exclude Candida or non-dermatophyte molds for which terbinafine is poorly active.
Option A: Option A is incorrect because terbinafine does not have broad-spectrum activity against Candida; completing the current course is unlikely to eradicate the Candida infection and exposes the patient to unnecessary drug without benefit.
Option B: Option B is incorrect because terbinafine is not merely fungistatic against Candida — it has genuinely limited activity against this organism, and extending the course duration does not compensate for the absence of meaningful anti-Candida activity at the target enzyme.
Option D: Option D is incorrect because Candida species are established causative pathogens of onychomycosis, particularly in immunocompromised patients and those with chronic mucocutaneous candidiasis; a positive culture should not be dismissed as contamination without clinical correlation.
Option E: Option E is incorrect because Candida albicans is not a dermatophyte — it is a yeast belonging to the kingdom Fungi but a completely different taxonomic genus and species from Trichophyton, Microsporum, or Epidermophyton dermatophytes; its susceptibility profile differs entirely.
20. During rounds, a resident asks how TDM (therapeutic drug monitoring) for flucytosine differs from TDM for vancomycin. The attending explains that both are renally cleared drugs requiring monitoring, but the specific toxicity thresholds and the measured parameters differ. Which of the following correctly describes the flucytosine TDM parameter and toxic threshold most relevant to the monitoring strategy?
A) Vancomycin and flucytosine share identical TDM strategies; both use AUC/MIC (area under the curve to minimum inhibitory concentration ratio) as the primary pharmacodynamic target, with the same 400 to 600 mg·h/L target range
B) Flucytosine TDM monitors the 2-hour post-dose peak concentration, with the goal of maintaining levels below 25 mg/L; concentrations above 25 mg/L are associated with nephrotoxicity
C) Flucytosine is monitored by trough concentration alone, targeting a trough of 50 to 100 mg/L; toxicity occurs when trough falls below 25 mg/L due to loss of antifungal pressure
D) Flucytosine TDM is based on volume of distribution calculations corrected for renal function; no blood sampling is required if serum creatinine is within normal limits
E) Flucytosine TDM monitors trough concentrations with the critical aim of keeping them below 100 mg/L; trough levels above this threshold are associated with concentration-dependent myelosuppression, while the 2-hour peak target of 25 to 50 mg/L ensures antifungal efficacy
ANSWER: E
Rationale:
Flucytosine TDM targets both efficacy and safety simultaneously. The 2-hour post-dose peak concentration target of 25 to 50 mg/L (some protocols use 40 to 60 mg/L for CNS infections) is the efficacy parameter ensuring adequate antifungal drug exposure at the site of infection. The critical safety parameter is the trough concentration: values above 100 mg/L are associated with a sharp increase in the risk of concentration-dependent myelosuppression (leukopenia, thrombocytopenia) arising from gut bacterial conversion of flucytosine to 5-fluorouracil (5-FU) at high systemic drug concentrations. Complete blood count (CBC) monitoring twice weekly is performed alongside TDM during flucytosine therapy. This dual-parameter approach — ensuring adequate peak for efficacy while limiting trough to avoid toxicity — distinguishes flucytosine TDM from vancomycin TDM, which now uses AUC/MIC targeting for a nephrotoxicity- and efficacy-driven pharmacodynamic endpoint.
Option A: Option A is incorrect because flucytosine TDM does not use AUC/MIC as its primary pharmacodynamic target, and the target ranges for vancomycin (AUC/MIC 400 to 600 mg·h/L) are not applicable to flucytosine; the drugs are monitored by entirely different parameters.
Option B: Option B is incorrect because the flucytosine peak target is 25 to 50 mg/L (not the upper safety threshold), and flucytosine toxicity manifests as myelosuppression, not nephrotoxicity; concentrations above 25 mg/L are within the therapeutic target range, not a toxicity signal.
Option C: Option C is incorrect because flucytosine TDM uses peak (not trough alone) as the primary efficacy target; the 50 to 100 mg/L range as a trough target would place patients near the toxic threshold rather than in the safe therapeutic zone.
Option D: Option D is incorrect because TDM requires actual blood sampling regardless of serum creatinine; creatinine-based dose adjustment tables are only an estimate, and TDM-measured concentrations are the definitive guide, especially in patients with changing renal function.
21. A medical student asks why the combination of amphotericin B (AmB) with flucytosine is considered synergistic rather than merely additive. Which of the following best describes the pharmacodynamic mechanism underlying this synergy?
A) Amphotericin B inhibits the fungal efflux pump Cdr1p, preventing active extrusion of flucytosine from the fungal cell and thereby maintaining high intracellular flucytosine concentrations
B) Amphotericin B disrupts the fungal cell membrane by binding ergosterol and creating ion-permeable channels, increasing membrane permeability and thereby enhancing intracellular uptake of flucytosine to concentrations that would not be achieved by flucytosine alone at the same dose
C) Amphotericin B inhibits CYP51 (lanosterol demethylase) in the fungal ergosterol pathway, depleting ergosterol and upregulating cytosine permease expression to increase flucytosine influx
D) Amphotericin B and flucytosine both target thymidylate synthase through independent binding sites, producing additive inhibition of DNA synthesis that collectively exceeds the sum of either agent alone
E) Synergy is pharmacokinetic rather than pharmacodynamic: amphotericin B inhibits renal tubular secretion of flucytosine, prolonging its half-life and increasing total drug exposure at the site of infection
ANSWER: B
Rationale:
The synergy between amphotericin B and flucytosine has a well-characterized pharmacodynamic mechanism. Amphotericin B binds to ergosterol in the fungal cell membrane and forms ion-permeable channels (pores), which disrupts membrane integrity and increases membrane permeability. This membrane disruption enhances the passive and active influx of flucytosine into the fungal cell, increasing intracellular flucytosine concentrations beyond what would be achieved by cytosine permease-mediated uptake alone. The increased intracellular flucytosine concentration potentiates its antimetabolite effect — inhibition of thymidylate synthase and disruption of RNA synthesis via its active metabolites — at doses that would be insufficient as monotherapy. Clinical evidence from randomized trials confirms that the combination achieves superior early fungicidal activity (faster CSF sterilization) compared to either agent alone in cryptococcal meningitis.
Option A: Option A is incorrect because amphotericin B does not act through inhibition of Cdr1p or other fungal efflux pumps; its mechanism involves direct ergosterol binding and membrane disruption, not efflux pump inhibition.
Option C: Option C is incorrect because amphotericin B does not inhibit CYP51 (that is the mechanism of azole antifungals); it binds ergosterol in the existing membrane, and the concept of upregulated cytosine permease expression is not the established mechanism of synergy.
Option D: Option D is incorrect because amphotericin B does not target thymidylate synthase; its mechanism is membrane disruption through ergosterol binding, entirely distinct from the nucleic acid synthesis disruption pathway of flucytosine.
Option E: Option E is incorrect because the synergy is pharmacodynamic (membrane permeabilization enhancing intracellular drug uptake), not pharmacokinetic; while amphotericin B does cause nephrotoxicity that reduces flucytosine renal clearance, this is a toxicity interaction requiring dose adjustment, not the mechanistic basis for antifungal synergy.
22. A 7-year-old child presents with tinea capitis, and fungal culture of scalp scrapings and broken hair shafts returns positive for Microsporum canis. The child's parent asks whether the newer drug terbinafine should be used instead of griseofulvin. Which statement best describes the current evidence-based position regarding species-specific drug selection for tinea capitis?
A) Terbinafine is universally preferred over griseofulvin for all species of tinea capitis, including Microsporum canis, based on its fungicidal mechanism and shorter required treatment duration regardless of species
B) Griseofulvin and terbinafine are pharmacologically interchangeable for all tinea capitis species; the choice should be based solely on local drug availability and cost, as clinical outcomes are identical
C) Terbinafine is preferred for Microsporum canis specifically because its squalene epoxidase target is constitutively overexpressed in Microsporum compared to Trichophyton, making M. canis inherently more susceptible
D) For tinea capitis caused by Microsporum canis, griseofulvin may be preferred over terbinafine because comparative trials have demonstrated that terbinafine achieves lower mycological cure rates against Microsporum species compared to Trichophyton species, where terbinafine is clearly superior
E) Neither terbinafine nor griseofulvin is appropriate for Microsporum canis tinea capitis; the current standard of care requires an oral azole such as itraconazole, which is the only agent with documented efficacy against Microsporum species
ANSWER: D
Rationale:
The selection of systemic antifungal therapy for tinea capitis depends on the causative species, and this species-specific distinction is clinically important. For tinea capitis caused by Trichophyton species (particularly T. tonsurans and T. violaceum), terbinafine has demonstrated superior mycological cure rates compared to griseofulvin in comparative trials, and terbinafine is preferred for these species. However, for tinea capitis caused by Microsporum species (particularly Microsporum canis, which is the predominant cause in many parts of Europe and is acquired from animals), comparative studies have shown that terbinafine achieves lower mycological cure rates against Microsporum than against Trichophyton. Griseofulvin is therefore the preferred or at least equally acceptable choice for M. canis tinea capitis in many guidelines and treatment centers, particularly where terbinafine has shown reduced efficacy for this species. This distinction is the basis for the recommendation to obtain fungal culture before initiating therapy wherever possible.
Option A: Option A is incorrect because the statement that terbinafine is universally preferred for all species regardless of organism is not supported by evidence; the species-specific difference in terbinafine efficacy between Microsporum and Trichophyton is the clinically important distinction that guides drug selection.
Option B: Option B is incorrect because griseofulvin and terbinafine are not interchangeable for all species; the species-specific efficacy difference, while center- and study-dependent, is sufficient that many guidelines differentiate by organism.
Option C: Option C is incorrect because constitutive overexpression of squalene epoxidase in Microsporum is not the established mechanism explaining terbinafine's activity pattern; the opposite is true — M. canis tends to be less susceptible to terbinafine than T. tonsurans in clinical outcomes, not more susceptible.
Option E: Option E is incorrect because both griseofulvin and terbinafine are appropriate systemic options for M. canis tinea capitis; while itraconazole has been used off-label, it is not the exclusive standard of care and griseofulvin with long-standing evidence and regulatory approval remains a first-line option for this indication.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.